Using the RSVpreF vaccine during pregnancy to prevent RSV infection in infants
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by An Duc Thien Le |
Posted on May 10th, 2023
|
Infection with respiratory syncytial virus (RSV) is a leading cause of death in children younger than 6 months old who live in low to middle income countries. Vaccinating the expecting mother can lead to transplacental transfer of protective antibodies, which have been effective against tetanus, pertussis, and SARS-CoV-2. Thus, a study, funded by Pfizer, was conducted to investigate whether the maternal immunization with the RSVpreF vaccine can be used to prevent illness in neonates
The phase 3 clinical trial included 7,358 women who have been pregnant between 24 and 36 weeks. These participants were randomly assigned to receive an intramuscular injection of either placebo or 120 micrograms of the bivalent RSV prefusion F protein–based (RSVpreF) vaccine. After birth, the health of the neonates were monitored every 30 days after the child had reached 3 months and until they reached 6 months of age. The researchers found that maternal immunization with the RSVpreF vaccine has an effectiveness rate of preventing severe RSV associated in neonates lower respiratory infection 90 days after birth was 81.8%; however the effectiveness rate reduced to 69.4% after 6 months. The effective rate at preventing any form of RSV infection of the lower respiratory tract was even lower, at only 57.1% - the researchers concluded that this is not clinically significant. Medical monitoring of the child continued until they were 2 years old. The researchers found that there was no significant difference in the rate of adverse events between the two groups.
The phase 3 clinical trial included 7,358 women who have been pregnant between 24 and 36 weeks. These participants were randomly assigned to receive an intramuscular injection of either placebo or 120 micrograms of the bivalent RSV prefusion F protein–based (RSVpreF) vaccine. After birth, the health of the neonates were monitored every 30 days after the child had reached 3 months and until they reached 6 months of age. The researchers found that maternal immunization with the RSVpreF vaccine has an effectiveness rate of preventing severe RSV associated in neonates lower respiratory infection 90 days after birth was 81.8%; however the effectiveness rate reduced to 69.4% after 6 months. The effective rate at preventing any form of RSV infection of the lower respiratory tract was even lower, at only 57.1% - the researchers concluded that this is not clinically significant. Medical monitoring of the child continued until they were 2 years old. The researchers found that there was no significant difference in the rate of adverse events between the two groups.